Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We've received very strong feedback from transplant centers, on the onboarding process on Gamida Cell Assist as a tool and resource and most importantly, on OMISIRGE's ability to fulfill an unmet need |
| We've made strong progress this quarter, which I'll go into detail on in a moment, but I would be remiss, if I didn't start this call by first acknowledging the courage and resilience of our Israeli team members who have shown incredible dedication and commitment to patients, as they continue operations to ensure, we reliably deliver OMISIRGE to patients in need, while living and working in a war zone |
| We were able to adapt and quickly overcome logistical challenges and our facilities remain operational, thanks to the dedication and resilience of our employees |
| We are incredibly proud of the effort of all of our global employees, as they have passionately worked within a lean launch team to ensure patients in need have access to Omisirge, every team member is honored to play a role in bringing Omisirge to patients in need |
| To recap, we remain confident in our team's ability to deliver Omisirge to an increasing volume of patients in need of a stem cell transplant in transplant centers across the US |
| We continue to make strong progress on the commercial launch of Omisirge, having exceeded our goals across both of the key metrics for launch of transplant center onboarding and market access |
| We believe, our early launch success is a promising sign of Omisirge's long-term potential to increase access and address critical unmet needs in stem cell transplantation |
| Although still in an early stage of the launch, we're very encouraged by what we are hearing |
| To see our team members demonstrate such resilience and strength in a challenging environment has been inspiring to witness |
| We believe in Omisirge’s ability to achieve its market potential and increase patient access to Allogeneic Stem Cell transplant |
| Given the pace of transplant center onboarding and the variability and time lines for preparing a patient for transplant, these numbers are in line with our expectations, and we are excited about the possibility that Omisirge will capture up to 20% market share at peak provided we are able to secure the necessary funding to support its fully resourced commercialization |
| And we are proud to be able to continue to serve our patients under these challenging circumstances |
| Over time, we expect the cost of sales and therefore the gross margins to improve measurably as production volumes scale to capacity |
| Overall, we're pleased with how onboarding is proceeding, having already exceeded our expectations for 2023 and considering the limited resources with which we launched |
| My team and I are engaged in conversations with physicians and staff at transplant centers across the country and the feedback we hear reinforces our confidence in the value of Omisirge |
| OMISIRGE has confirmed coverage with US payers, hovering more than 90% of commercial lives, exceeding our full year goal of 70% |
| Our lean launch has continued to exceed our expectations across the two key metrics we defined for launch, transplant center onboarding and market access for patients |
| We are generally seeing patients that are consistent with what we believe would meet the promise of Omisirge to both increase access and improve outcomes |
| With strong interest in Omisirge from transplant centers, including centers that were not part of the Phase 3 trial has continued to grow since our last update |
| I'm pleased to share that Gamida Cell is reporting revenue for the first time in its history |
| We are so proud to provide OMISIRGE, a potentially life-saving cell therapy, for those in need of a transplant donor source |
| I'm happy |
| We believe this increase in authorized shares will provide us with the increased flexibility necessary to finance our operations |
| We are thrilled to see increasing demand for Omisirge and are working to ensure that all patients in need have access to our NAM modified cell therapy |
| We're pleased to continue to work with transplant centers and academic institutions to further the availability of Omisirge and to add to the body of scientific evidence about the mechanism and potential of our innovative NAM technology |
| So in summary, our lean launch is proceeding ahead of our expectations, and we expect to maintain our lean launch approach to expand the number of onboarded transplant centers and patients receiving Omisirge into 2024 |
| We are proud to report our first Omisirge deliveries, an official transition into being a commercial stage revenue reporting company, expecting to deliver a total of four to six units for the full year 2023 |
| As Michelle stated earlier, we continue to see growing interest in Omisirge from transplant centers |
| And what physicians do is, they really choose the best potential graft source for their patient of the available choices |
| This is why it is so critical for us to focus our resources in the first month of launch on accelerating transplant center onboarding by exceeding our initial target range of 10 to 15 centers, we are in a position to increase the number of patients receiving Omisirge |
| Statement |
|---|
| The gross to net allowances and deductions were particularly low in the third quarter given the confirmed insurance coverage and transplant status for those patients |
| As you might imagine, the process of getting cells into Israel and delivering OMISIRGE back to transplant centers in the US, could have been impacted when many airlines suspended flight service in Israel |
| Additionally, excess capacity costs of $2.2 million associated with our manufacturing facility were recorded in SG&A in the third quarter |
| Our employee safety is a key concern |
| With the Omisirge launch ongoing and additional patients enrolled in GamidaCell Assist, one of the four most concerns for business continuity was ensuring that we could transport Omisirge out of our manufacturing facility and to patients |
| Our net loss in the third quarter was $1.5 million compared to a net loss of $17.8 million in the third quarter of 2022, driven primarily by the $17.2 million change in financial income, as just discussed |
| But unfortunately, we're not able to find a donor source before Omisirge approval |
| As we end 2023 and prepare to enter 2024, we will continue to maintain our lean launch efforts, due to resource constraints as we pursue additional funding |
| Our actual results may differ materially from what we project today due to a number of important factors, including those related to clinical, scientific, regulatory and technical developments and those inherent in the process of developing and commercializing products candidates that are safe and effective for use as human therapeutics and in the endeavor of building a business around our product and product candidate, as well as those considerations described in the Risk Factors section of our most recent quarterly report on Form 10-Q and other filings that we may make with the SEC from time to time |
Please consider a small donation if you think this website provides you with relevant information